Tuesday, November 15, 2005

Lipitor doesn't beat Zocor in heart attack study

ABC News: High doses of Pfizer Inc.'s cholesterol-lowering drug Lipitor failed in a high-stakes trial to help heart attack patients significantly more than moderate doses of Merck & Co.'s rival Zocor, researchers said on Nov. 15, 2005.

The aim of the study presented at the American Heart Association scientific meeting was to determine whether intensive lowering of "bad" LDL cholesterol with atorvastatin (Lipitor) would reduce the risk of death and other adverse events in heart attack patients more than the moderate, most widely used dose of Zocor, known by the chemical name simvastatin.


Post a Comment

<< Home